Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential cation channel subfamily V member 1 (TRPV1) is a non-selective cation channel primarily expressed in nociceptive sensory neurons, where it serves as a critical integrator of thermal and chemical pain signals (Source: UniProt P53767). It is activated by temperatures above 43 degrees Celsius, acidic conditions, and vanilloid compounds such as capsaicin, leading to cation influx and neuronal depolarization. The activity of TRPV1 is dynamically regulated by various G protein-coupled receptors (GPCRs), including bradykinin, prostaglandin, and protease-activated receptors, which sensitize the channel via intracellular signaling cascades like the PKC and PKA pathways (Source: PubMed PMID: 12068335). This sensitization is a hallmark of inflammatory and neuropathic pain, making the TRPV1-GPCR axis a major focus for analgesic drug development. While TRPV1 antagonists have shown efficacy in preclinical models, their clinical utility has been limited by significant safety concerns, most notably hyperthermia and a reduced ability to sense scalding heat (Source: PubMed PMID: 18384699). Consequently, therapeutic strategies have shifted toward potent TRPV1 agonists that induce long-term desensitization or targeting the specific GPCRs that modulate channel activity.
TRPV1 functions as a non-selective cation channel that integrates noxious stimuli; associated GPCRs modulate its sensitivity via intracellular signaling pathways like PKC and PKA, which lower the channel's activation threshold.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential cation channel subfamily V member 1 and associated G protein-coupled receptors (TRPV1/GPCRs).